vs

Side-by-side financial comparison of American Well Corp (AMWL) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

American Well Corp is the larger business by last-quarter revenue ($55.3M vs $28.8M, roughly 1.9× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs -45.1%, a 46.0% gap on every dollar of revenue.

The American Tobacco Company was a tobacco company founded in 1890 by J. B. Duke through a merger between a number of U.S. tobacco manufacturers including Allen and Ginter, Goodwin & Company, and Kinney Brothers. The company was one of the original 12 members of the Dow Jones Industrial Average in 1896. The American Tobacco Company dominated the industry by acquiring the Lucky Strike Company and over 200 other rival firms. Federal Antitrust action begun in 1907 broke the company into several ...

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

AMWL vs XFOR — Head-to-Head

Bigger by revenue
AMWL
AMWL
1.9× larger
AMWL
$55.3M
$28.8M
XFOR
Higher net margin
XFOR
XFOR
46.0% more per $
XFOR
1.0%
-45.1%
AMWL

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
AMWL
AMWL
XFOR
XFOR
Revenue
$55.3M
$28.8M
Net Profit
$-24.9M
$282.0K
Gross Margin
83.6%
Operating Margin
-45.5%
-32.8%
Net Margin
-45.1%
1.0%
Revenue YoY
-22.1%
Net Profit YoY
41.6%
100.5%
EPS (diluted)
$-1.53
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMWL
AMWL
XFOR
XFOR
Q4 25
$55.3M
Q3 25
$56.3M
Q2 25
$70.9M
Q1 25
$66.8M
$28.8M
Q4 24
$71.0M
Q3 24
$61.0M
Q2 24
$62.8M
Q1 24
$59.5M
$0
Net Profit
AMWL
AMWL
XFOR
XFOR
Q4 25
$-24.9M
Q3 25
$-32.4M
Q2 25
$-19.7M
Q1 25
$-18.7M
$282.0K
Q4 24
$-42.7M
Q3 24
$-43.5M
Q2 24
$-49.9M
Q1 24
$-72.1M
$-51.8M
Gross Margin
AMWL
AMWL
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
83.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
AMWL
AMWL
XFOR
XFOR
Q4 25
-45.5%
Q3 25
-52.1%
Q2 25
-28.7%
Q1 25
-45.5%
-32.8%
Q4 24
-60.2%
Q3 24
-77.6%
Q2 24
-83.4%
Q1 24
-126.1%
Net Margin
AMWL
AMWL
XFOR
XFOR
Q4 25
-45.1%
Q3 25
-57.5%
Q2 25
-27.8%
Q1 25
-28.0%
1.0%
Q4 24
-60.1%
Q3 24
-71.2%
Q2 24
-79.5%
Q1 24
-121.1%
EPS (diluted)
AMWL
AMWL
XFOR
XFOR
Q4 25
$-1.53
Q3 25
$-2.00
Q2 25
$-1.24
Q1 25
$-1.19
$0.04
Q4 24
$-2.71
Q3 24
$-2.87
Q2 24
$-3.36
Q1 24
$-4.94
$-7.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMWL
AMWL
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$182.3M
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$235.6M
$22.9M
Total Assets
$323.8M
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMWL
AMWL
XFOR
XFOR
Q4 25
$182.3M
Q3 25
$200.9M
Q2 25
$219.1M
Q1 25
$222.4M
$40.3M
Q4 24
$228.3M
Q3 24
$244.6M
Q2 24
$276.9M
Q1 24
$308.6M
$60.5M
Total Debt
AMWL
AMWL
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
$75.0M
Q4 24
Q3 24
Q2 24
Q1 24
$55.0M
Stockholders' Equity
AMWL
AMWL
XFOR
XFOR
Q4 25
$235.6M
Q3 25
$254.9M
Q2 25
$282.6M
Q1 25
$294.0M
$22.9M
Q4 24
$304.8M
Q3 24
$336.7M
Q2 24
$363.9M
Q1 24
$408.7M
$1.0M
Total Assets
AMWL
AMWL
XFOR
XFOR
Q4 25
$323.8M
Q3 25
$359.4M
Q2 25
$388.7M
Q1 25
$419.5M
$130.0M
Q4 24
$436.0M
Q3 24
$483.0M
Q2 24
$507.8M
Q1 24
$548.4M
$112.2M
Debt / Equity
AMWL
AMWL
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
3.27×
Q4 24
Q3 24
Q2 24
Q1 24
53.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMWL
AMWL
XFOR
XFOR
Operating Cash FlowLast quarter
$-17.4M
$-12.4M
Free Cash FlowOCF − Capex
$-17.4M
FCF MarginFCF / Revenue
-31.4%
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
-43.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMWL
AMWL
XFOR
XFOR
Q4 25
$-17.4M
Q3 25
$-18.8M
Q2 25
$-4.7M
Q1 25
$-25.1M
$-12.4M
Q4 24
$-13.4M
Q3 24
$-32.4M
Q2 24
$-21.8M
Q1 24
$-59.8M
$-33.6M
Free Cash Flow
AMWL
AMWL
XFOR
XFOR
Q4 25
$-17.4M
Q3 25
Q2 25
Q1 25
$-25.1M
Q4 24
$-13.4M
Q3 24
$-32.4M
Q2 24
$-21.8M
Q1 24
$-59.8M
$-33.7M
FCF Margin
AMWL
AMWL
XFOR
XFOR
Q4 25
-31.4%
Q3 25
Q2 25
Q1 25
-37.6%
Q4 24
-18.9%
Q3 24
-53.0%
Q2 24
-34.7%
Q1 24
-100.5%
Capex Intensity
AMWL
AMWL
XFOR
XFOR
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
0.0%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
AMWL
AMWL
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
-43.86×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMWL
AMWL

Platform Subscription$28.8M52%
Visits$23.7M43%
Others$2.8M5%

XFOR
XFOR

Segment breakdown not available.

Related Comparisons